BioPharmSignal logoBioPharmSignal

Biotech News

BioCryst to Present New Real-World Evidence Underscoring the Ongoing Burden of Pediatric Hereditary Angioedema at ISPOR 2026

BioCryst Pharmaceuticals (BCRX)BioCryst PharmaceuticalsConference / presentation

RESEARCH TRIANGLE PARK, N.C., May 13, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present new real-world evidence at the 2026 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) conference taking place in

Related news

BCRXBioCryst Pharmaceuticals2026-09-01 11:00 EST

BioCryst to Present at Upcoming Investor Conference

TARAProtara Therapeutics2026-09-08 20:05 EST

Protara Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference

KRYSKrystal Biotech2026-09-03 12:00 EST

Krystal Biotech to Present at 2026 Cantor Global Healthcare Conference

BCRXBioCryst Pharmaceuticals2026-10-05 11:00 EST

BioCryst Announces Formation of Scientific Advisory Board to Drive Rare Disease Pipeline Innovation and Growth

ARWRArrowhead Pharmaceuticals2026-09-03 11:30 EST

Arrowhead Pharmaceuticals to Participate in Upcoming September 2026 Investor Conferences

ETONEton Pharmaceuticals2026-08-27 10:50 EST

Eton Pharmaceuticals to Participate at 2026 Wells Fargo Healthcare Conference

EXELExelixis2026-09-01 20:05 EST

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in September

PTCTPTC Therapeutics, Inc.2026-08-27 12:00 EST

PTC Therapeutics to Participate in Upcoming Investor Conferences

PHARPharming Group2026-09-09 06:00 EST

Pharming Group to participate in September investor conferences

GSKGSK plc2026-09-10 07:00 EST

GSK’s Shingrix (Recombinant Zoster Vaccine) prefilled syringe presentation approved in Japan

View all latest news

BioCryst Pharmaceuticals

Rare-Disease Drug Development BioCryst Pharmaceuticals discovers, develops and commercializes small-molecule medicines for rare diseases. Its portfolio combines a marketed hereditary angioedema franchise with clinical programs targeting additional protein-mediated disorders. ORLADEYO Commercial Franchise ORLADEYO is an oral preventive...

Recent company news

BCRXBioCryst Pharmaceuticals2026-10-05 11:00 EST

BioCryst Announces Formation of Scientific Advisory Board to Drive Rare Disease Pipeline Innovation and Growth

BCRXBioCryst Pharmaceuticals2026-09-01 11:00 EST

BioCryst to Present at Upcoming Investor Conference

BCRXBioCryst Pharmaceuticals2026-08-05 11:00 EST

BioCryst Reports Second Quarter 2026 Financial Results

BCRXBioCryst Pharmaceuticals2026-07-22 11:00 EST

BioCryst to Report Second Quarter 2026 Financial Results on August 5

BCRXBioCryst Pharmaceuticals2026-07-15 11:00 EST

BioCryst Appoints David W. Jenkins as Chief Scientific Officer

Stock data

Close
7.95 USD
Market cap
2.12B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States